{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:39:32Z","timestamp":1757619572186,"version":"3.44.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Research Future Fund","award":["MRF2014921"],"award-info":[{"award-number":["MRF2014921"]}]},{"DOI":"10.13039\/501100023410","name":"Snow Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-08965-w","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T09:19:12Z","timestamp":1753435152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bringing optimised COVID-19 vaccine schedules to immunocompromised populations: statistical elements and design"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4881-2860","authenticated-orcid":false,"given":"Michael","family":"Dymock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Hagenauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom L.","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie A.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On\u00a0behalf\u00a0of\u00a0the\u00a0BOOST-IC\u00a0Investigator Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"4","key":"8965_CR1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1089\/aid.2021.0007","volume":"37","author":"M Weerasuria","year":"2021","unstructured":"Weerasuria M, Ko C, Ehm A, O\u2019Bryan J, et al. The impact of the COVID-19 pandemic on people living with HIV in Victoria, Australia. AIDS Res Hum Retrovir. 2021;37(4):322\u20138.","journal-title":"AIDS Res Hum Retrovir."},{"issue":"4","key":"8965_CR2","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/jmv.27487","volume":"94","author":"K Mohamed","year":"2022","unstructured":"Mohamed K, Rzymski P, Islam MS, Makuku R, Mushtaq A, Khan A, et al. COVID-19 vaccinations: The unknowns, challenges, and hopes. J Med Virol. 2022;94(4):1336\u201349.","journal-title":"J Med Virol."},{"issue":"25","key":"8965_CR3","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood.2020008824","volume":"136","author":"A Vijenthira","year":"2020","unstructured":"Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881\u201392.","journal-title":"Blood."},{"issue":"1","key":"8965_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S2352-3018(20)30305-2","volume":"8","author":"K Bhaskaran","year":"2021","unstructured":"Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021;8(1):24\u201332.","journal-title":"Lancet HIV."},{"key":"8965_CR5","doi-asserted-by":"publisher","unstructured":"Yamanaga S, Shimata K, Ohfuji S, Yoshikawa M, Natori Y, Hibi T, et al. Excess mortality in COVID-19-affected solid organ transplant recipients across the pandemic. Am J Transplant. 2024. https:\/\/doi.org\/10.1016\/j.ajt.2024.03.016.","DOI":"10.1016\/j.ajt.2024.03.016"},{"issue":"18","key":"8965_CR6","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1056\/NEJMp2027405","volume":"383","author":"M Slaoui","year":"2020","unstructured":"Slaoui M, Hepburn M. Developing Safe and Effective Covid Vaccines \u2013 Operation Warp Speed\u2019s Strategy and Approach. N Eng J Med. 2020;383(18):1701\u20133.","journal-title":"N Eng J Med."},{"key":"8965_CR7","doi-asserted-by":"publisher","unstructured":"McLeod C, Ramsay J, Flanagan KL, Plebanski M, Marshall H, Dymock M, et\u00a0al. Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO). Trials. 2023;24(202). https:\/\/doi.org\/10.1186\/s13063-023-07225-z.","DOI":"10.1186\/s13063-023-07225-z"},{"issue":"16","key":"8965_CR8","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1001\/jama.2015.2316","volume":"313","author":"SM Berry","year":"2015","unstructured":"Berry SM, Connor JT, Lewis RJ. The Platform Trial: An Efficient Strategy for Evaluating Multiple Treatments. JAMA. 2015;313(16):1619\u201320. https:\/\/doi.org\/10.1001\/jama.2015.2316.","journal-title":"JAMA."},{"issue":"3","key":"8965_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/1740774515626362","volume":"13","author":"BR Saville","year":"2016","unstructured":"Saville BR, Berry SM. Efficiencies of platform clinical trials: A vision of the future. Clin Trials. 2016;13(3):358\u201366. https:\/\/doi.org\/10.1177\/1740774515626362.","journal-title":"Clin Trials."},{"issue":"7","key":"8965_CR10","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.clinthera.2020.05.010","volume":"42","author":"EL Meyer","year":"2020","unstructured":"Meyer EL, Mesenbrink P, Dunger-Baldauf C, Li Y, Posch M, K\u00f6nig F. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. Clin Ther. 2020;42(7):1330\u201360. https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.010.","journal-title":"Clin Ther."},{"key":"8965_CR11","doi-asserted-by":"publisher","unstructured":"Griffin DWJ, Dymock M, Wong G, Morrissey CO, Lewin SR, et al. Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial. Trials. 2024;25(485). https:\/\/doi.org\/10.1186\/s13063-024-08315-2.","DOI":"10.1186\/s13063-024-08315-2"},{"key":"8965_CR12","doi-asserted-by":"publisher","unstructured":"Dymock M, McLeod C, Richmond P, Snelling T, Marsh JA. Statistical considerations for the platform trial in COVID-19 vaccine priming and boosting. Trials. 2024;25(507). https:\/\/doi.org\/10.1186\/s13063-024-08343-y.","DOI":"10.1186\/s13063-024-08343-y"},{"key":"8965_CR13","doi-asserted-by":"publisher","unstructured":"Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian Data Analysis (3rd Edition). United States: Chapman and Hall\/CRC; 2013. https:\/\/doi.org\/10.1201\/b16018.","DOI":"10.1201\/b16018"},{"issue":"22","key":"8965_CR14","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1001\/jama.2018.17977","volume":"320","author":"AE McGlothlin","year":"2018","unstructured":"McGlothlin AE, Viele K. Bayesian Hierarchical Models. JAMA. 2018;320(22):2365\u20136. https:\/\/doi.org\/10.1001\/jama.2018.17977.","journal-title":"JAMA."},{"key":"8965_CR15","doi-asserted-by":"publisher","unstructured":"Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian Adaptive Methods for Clinical Trials (1st Edition). United States: CRC Press; 2010. https:\/\/doi.org\/10.1201\/EBK1439825488.","DOI":"10.1201\/EBK1439825488"},{"key":"8965_CR16","unstructured":"E9(R1) Statistical principles for clinical trials: addendum: estimands and sensitivity analysis in clinical trials. https:\/\/www.fda.gov\/media\/108698\/download. Accessed 20 Feb 2023."},{"issue":"5","key":"8965_CR17","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1177\/17407745221112013","volume":"19","author":"BR Saville","year":"2022","unstructured":"Saville BR, Berry DA, Berry NS, Viele K, Berry SM. The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials. Clin Trials. 2022;19(5):490\u2013501. https:\/\/doi.org\/10.1177\/17407745221112013.","journal-title":"Clin Trials."},{"key":"8965_CR18","doi-asserted-by":"publisher","unstructured":"Bofill\u00a0Roig M, Krotka P, Burman CF, Glimm E, Gold SM, et al. On model-based time trend adjustments in platform trials with non-concurrent controls. BMC Med Res Methodol. 2022;22(228). https:\/\/doi.org\/10.1186\/s12874-022-01683-w.","DOI":"10.1186\/s12874-022-01683-w"},{"key":"8965_CR19","doi-asserted-by":"publisher","unstructured":"Mahar RK, McGlothlin A, Dymock M, Lee TC, Lewis RJ, et al. A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial. Trials. 2023;24(795). https:\/\/doi.org\/10.1186\/s13063-023-07718-x.","DOI":"10.1186\/s13063-023-07718-x"},{"issue":"8","key":"8965_CR20","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/S0196-0644(05)80119-2","volume":"22","author":"RJ Lewis","year":"1993","unstructured":"Lewis RJ, Wears RL. An introduction to the Bayesian analysis of clinical trials. Ann Emerg Med. 1993;22(8):1328\u201336.","journal-title":"Ann Emerg Med."},{"issue":"10318","key":"8965_CR21","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","volume":"298","author":"APS Munro","year":"2021","unstructured":"Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;298(10318):2258\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(21)02717-3.","journal-title":"Lancet."},{"key":"8965_CR22","doi-asserted-by":"crossref","unstructured":"Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan: A probabilistic programming language. J Stat Softw. 2017;76(1):1-32.","DOI":"10.18637\/jss.v076.i01"},{"key":"8965_CR23","unstructured":"Gabry J, \u010ce\u0161novar R, Johnson A. cmdstanr: R Interface to \u2018CmdStan\u2019; 2022. https:\/\/mc-stan.org\/cmdstanr\/, https:\/\/discourse.mc-stan.org. Accessed 31 Jan 2025."},{"key":"8965_CR24","unstructured":"Team RC. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2022. https:\/\/www.R-project.org\/. Accessed 31 Jan 2025."},{"key":"8965_CR25","doi-asserted-by":"publisher","unstructured":"Denholm JT, Venkatesh B, Davis J, Bowen AC, Hammond NE, Jha V, et\u00a0al. ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial. Trials. 2022;75(1014). https:\/\/doi.org\/10.1186\/s13063-022-06929-y.","DOI":"10.1186\/s13063-022-06929-y"},{"key":"8965_CR26","doi-asserted-by":"publisher","unstructured":"Angus DC, Berry S, Lewis R, Al-Beidh F, Arabi Y, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study Rationale and Design. Ann Am Thorac Soc. 2020;17(7). https:\/\/doi.org\/10.1513\/AnnalsATS.202003-192SD.","DOI":"10.1513\/AnnalsATS.202003-192SD"},{"issue":"11","key":"8965_CR27","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/cid\/ciac476","volume":"75","author":"SYC Tong","year":"2022","unstructured":"Tong SYC, Mora J, Bowen AC, Cheng MP, Daneman N, Goodman AL, et al. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. Clin Infect Dis. 2022;75(11):2027\u201334. https:\/\/doi.org\/10.1093\/cid\/ciac476.","journal-title":"Clin Infect Dis."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08965-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T23:13:57Z","timestamp":1757286837000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08965-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8965"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08965-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the conduct of this study has been provided by the Alfred Ethics Committee (122\/22). Informed consent to participate will be obtained from all participants in either written or electronic form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent form are available from the corresponding author on request and will be available on the trial website.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}